Circassia Pharma
Northbrook House
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA
United Kingdom
Website: http://www.circassia.co.uk/
57 articles with Circassia Pharma
-
Circassia Limited Interim Management Statement
11/11/2014
-
Circassia Limited Raises $332 Million In IPO Debut, Largest Biotech IPO Since 1995
3/14/2014
-
Circassia Limited Seeks $285 Million In One Of Europe's Biggest Biotech IPOs
2/6/2014
-
Circassia Limited Appoints Paul R Edick to Its Board of Directors
10/17/2013
-
Circassia Limited's Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season
10/1/2013
-
Circassia Limited Appoints Dr. Francesco Granata as Chairman
9/25/2013
-
Circassia Limited's Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction
9/12/2013
-
Circassia Limited's Cat Allergy Treatment Shows Sustained Symptom Improvement
2/25/2013
-
Circassia Limited Appoints Dr Jean-Jacques Garaud to Its Board of Directors
12/6/2012
-
Circassia Limited Initiates Pivotal Phase 3 ToleroMune® Trial in Cat Allergen-Induced Rhinoconjunctivitis
10/4/2012
-
Circassia Limited Announces Publication of ToleroMune® Cat Allergy Treatment Clinical Results in Journal of Allergy and Clinical Immunology
9/27/2012
-
Circassia Limited Appoints Dr Brett Haumann as Chief Medical Officer
9/11/2012
-
National Institutes of Health (NIH) Awards $6.4 Million to Professor Mark Larche to Investigate Mechanisms of Allergy Tolerance Generated by Circassia Limited's ToleroMune® Treatment
6/7/2012
-
Circassia Limited's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
3/8/2012
-
Circassia Limited's Hay Fever Treatment Improves Patients’ Allergy Symptoms in Phase II Clinical Trial
9/27/2011
-
Circassia Limited's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial
9/27/2011
-
Circassia Limited's Rapid Four-Dose ToleroMune® Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up
6/13/2011
-
Circassia Limited's Rapid Four-Dose ToleroMune(R) Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up
6/13/2011
-
Circassia Limited Completes $98 Million Fundraising for Final-Stage Development of Lead Allergy Products
4/19/2011
-
Circassia Limited Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment from Airmid Inc.
2/9/2011